

# Influenza Treatment Market to Garner \$1.22 Billion by 2026 at 4.5% CAGR

*increase in healthcare expenditure worldwide & surge in R&D investments for discovery of new drugs have propelled the growth of the influenza treatment market.*

PORTLAND, OR, UNITED STATES,  
September 29, 2021 /

EINPresswire.com/ -- Allied Market Research recently published a report, titled, "Influenza Treatment Market by Product Type (Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, and Others) and Distribution

Channel (Retail Pharmacy, Hospital Pharmacy, and Others), Global Opportunity Analysis and Industry Forecast, 2019–2026". According to the report, the global influenza treatment industry was pegged at \$861.5 million in 2018, and is projected to hit \$1.22 billion by 2026, growing at a CAGR of 4.5% from 2019 to 2026.

### Major drivers for the market growth

Increase in incidences of influenza across the globe, rise in healthcare expenditure worldwide, and rise in R&D investments for discovery of new drugs have boosted the growth of the global influenza treatment market. However, presence of substitutes for the treatment of influenza hamper the market growth. On the contrary, high growth potential in developing countries is expected to create lucrative opportunities in the near future.

Request Sample Report at: <https://www.alliedmarketresearch.com/request-sample/6471>

### Oseltamivir Phosphate segment dominated the market

Based on type, the oseltamivir phosphate segment held the largest share in 2018, accounting for more than two-fifths of the global influenza treatment market. Oseltamivir is recommended by CDC and the American Academy of Pediatrics (AAP) for early treatment of flu in people of any



Industry for Influenza Treatment

age, which propels the growth of the segment. However, the baloxavir marboxil segment is projected to manifest the highest CAGR of 4.6% during the forecast period. Baloxavir marboxil drug is effective against strains of influenza A that are resistant to oseltamivir. Thus, this makes it a preferred choice in treatment of influenza, hence boosting the growth of the segment.

The retail pharmacy segment to manifest CAGR through 2026

Based on distribution channel, the retail pharmacy segment is projected to register the highest CAGR of 4.7% during the forecast period. In addition, the same segment held the largest share in 2018, accounting for nearly half of the global influenza treatment market. This is owing to the strong presence of retail pharmacies around the globe and convenience offered by them. The research also analyzes segments including hospital pharmacy and others.

North America held the lion's share

The market across North America held the largest share in 2018, contributing to around one-third of the market. This is owing to surge in prevalence of influenza infection in the region. However, the global influenza treatment market across Asia-Pacific is estimated to portray the fastest CAGR of 5.6% during the forecast period. This is due to surge in the awareness towards early diagnosis of the medical condition for better treatment surge in the awareness towards early diagnosis of the medical condition for better treatment.

Major market players

AstraZeneca Plc  
BioCryst Pharmaceuticals, Inc.  
Daiichi Sankyo Company Limited  
F. Hoffmann-La Roche AG  
GlaxoSmithKline Plc  
Mylan N.V  
Natco Pharma Limited  
Novartis AG  
Sanofi  
Teva Pharmaceutical Industries Limited

Know More: <https://www.alliedmarketresearch.com/influenza-treatment-market-A06106>

Trending Reports:

[Cardiovascular & Soft Tissue Repair Patches Market](#)- Global Opportunity Analysis and Industry Forecasts

[Cardiovascular Digital Solutions Market](#)- Global Opportunity Analysis and Industry Forecast

[Marine Derived Pharmaceuticals Market](#)- Opportunity Analysis and Industry Forecast

David Correa  
Allied Analytics LLP  
+1 503-894-6022

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/552629072>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.